cas 1201-26-9|| where to buy 3-Indolylacetone

Product Name:3-Indolylacetone

IUPAC Name:1-(1H-indol-3-yl)propan-2-one

Packing Unit	Available Stock	Price($)	Quantity
CM148642-25g	in stock	ȡǶǜ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1201-26-9 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:1201-26-9; Molecular Formula:C11H11NO; Melting Point:-; Smiles Code:CC(CC1=CNC2=C1C=CC=C2)=O; Density:

: Catalog Number:CM148642; Molecular Weight:173.22; Boiling Point:341.7°C at 760 mmHg; MDL No:MFCD00047187; Storage:Store at 2-8°C.

: Indoles; Indole is a compound of pyrrole and benzene in parallel, also known as benzopyrrole. There are two combinations of pyrrole and benzene, called indole and isoindole, respectively. Many derivatives of indole have physiological and pharmacological activities, and can synthesize vasodilators, antihistamines, antipyretic analgesics, etc. in medicine, so indole is also a very important heterocyclic compound.; indole company; As a indole company,we sincerely welcome the new and old friends from home and abroad to synergize with our company and share the benefits and opportunities.

: Palazestrant; Olema Oncology is advancing the development of Palazestrant (OP-1250) in metastatic breast cancer in 2024. Palazestrant is an oral complete ER antagonist (CERAN) and selective ER degrader (SERD). It potently binds and completely blocks transcriptional activity of both wild-type and ESR1-mutant ER with favorable tolerability and anti-tumor activity.
Palazestrant is under clinical development both in combination with Novartis' CDK4/6 inhibitor Kisqali (Ribociclib) as a first-line therapy for advanced estrogen receptor-positive, HER2-negative breast cancer, and as a monotherapy compared to standard of care treatment in second- and third-line advanced or metastatic ER-positive, HER2-negative breast cancer.